HOME ·

01877.HK

Junshi Biosciences (01877.HK): Toripalimab NSCLC Indication Supplemental Application Accepted; Expanded from Stage IIIA-IIIB to Stage II-III
Tags：
JUNSHI BIO01877.HK
2026-07-21
Junshi Biosciences (01877.HK): Signs Licensing Agreement with Fosun Wampo; Receives RMB215 Million Upfront and Up to RMB1.125 Billion Milestones
Tags：
JUNSHI BIO01877.HK
2026-07-01
JUNSHI BIO(01877.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at loss of CNY 20.56 million, loss narrowed by 91.24% YoY
Tags：
JUNSHI BIO01877.HKnarrow losses
2026-04-28